HomeBUSINESS
BUSINESS

Perspective on Takeda/Shire Deal - 1: Profits Delivered by On-Market Products More Important than Pipeline
(May.29.2018)

Atsushi Seki, Executive Director, UBS Investment Research, Analyst, Japan Pharmaceuticals Sector, Equity Research, Global Research Division, UBS Securities Japan
Will Takeda Pharmaceutical’s Shire acquisition turn out to be a success or failure? We asked industry pundits about what drove the Japanese giant’s pursuit for the bigger rival and what the future of the £46 billion deal holds. For the first of this series, UBS analyst Atsushi Seki sat with Jiho to give his take ...
(LOG IN FOR FULL STORY)